Howard Kaufman

Summary

Affiliation: Rush University Medical Center
Country: USA

Publications

  1. doi request reprint OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma
    Howard L Kaufman
    The Tumor Immunology Laboratory and Department of General Surgery, Rush University Medical Center, Chicago, IL 60612, USA
    Future Oncol 6:941-9. 2010
  2. pmc First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients
    Neil L Berinstein
    Sunnybrook Health Sciences Center, Toronto, ON, Canada
    J Transl Med 10:156. 2012
  3. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  4. pmc Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression
    Xiulong Xu
    Department of General Surgery, Rush University Medical Center, Chicago, IL 60612, USA
    BMC Cancer 11:194. 2011
  5. doi request reprint Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma
    Howard L Kaufman
    Department of Surgery, Medicine and Immunology, Rush University Medical Center, Chicago, IL, USA
    Ann Surg Oncol 17:718-30. 2010

Collaborators

  • Neil L Berinstein
  • Kunle Odunsi
  • Xiulong Xu
  • Bernard A Fox
  • Rita Nigam
  • Michael A Morse
  • Marianne M Stanford
  • Mohan Karkada
  • Leeladhar Sammatur
  • Gurkamal Chatta
  • Marc Mansour
  • Genevieve M Weir
  • Lisa D MacDonald
  • John J Nemunaitis
  • Michael Papamichail
  • Shukui Qin
  • Jared A Gollob
  • Ena Wang
  • Elizabeth M Jaffee
  • Laurence Zitvogel
  • Jerome Galon
  • Sjoerd H van der Burg
  • Janet Plate
  • Ulrich Keilholtz
  • Lisa H Butterfield
  • Alfred E Chang
  • Koji Kawakami
  • Jon M Wigginton
  • Rik J Scheper
  • Dolores J Schendel
  • Robert Rees
  • Kristen Hege
  • Andrea Nicolini
  • Jill O'Donnell-Tormey
  • Ernest Borden
  • Harry Dolstra
  • Thomas F Gajewski
  • Enrico Proietti
  • Yutaka Kawakami
  • Michael B Atkins
  • Harpreet Singh-Jasuja
  • William E Carson
  • Antoni Ribas
  • Ronald B Herberman
  • Sylvia Janetzki
  • Glenn Dranoff
  • Tanja de Gruijl
  • Fabio Grizzi
  • Christian Ottensmeier
  • Marij Jp Welters
  • Pamela S Ohashi
  • Cedrik M Britten
  • Francesco M Marincola
  • Robert O Dillman
  • Lothar Bergmann
  • Ruggero Ridolfi
  • James H Finke
  • Heinz Zwierzina
  • Barbara Seliger
  • Paul von Hoegen
  • Hiroshi Shiku
  • Pawel Kalinski
  • Giorgio Parmiani
  • Beatrix Kotlan
  • Pedro J Romero
  • Cecile Gouttefangeas
  • Padmanee Sharma
  • Guido Kroemer
  • Rejean Lapointe
  • Giuseppe Masucci
  • William J Murphy
  • Paolo Antonio Ascierto
  • F Stephen Hodi
  • Jirina Bartunkova
  • A Raja Choudhury
  • Michael J Mastrangelo
  • Michael T Lotze
  • Geetha S Rao
  • Cristina C Bonorino
  • Tara Withington
  • Leif Hakansson
  • Thomas Spies
  • Veronika Groh
  • Brad Nelson
  • Jedd D Wolchok
  • Hyam I Levitsky
  • Ignacio Melero
  • Lloyd J Old
  • Neil Berinstein
  • Carl H June

Detail Information

Publications5

  1. doi request reprint OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma
    Howard L Kaufman
    The Tumor Immunology Laboratory and Department of General Surgery, Rush University Medical Center, Chicago, IL 60612, USA
    Future Oncol 6:941-9. 2010
    ..The rationale, study design, end points and future development of the Oncovex(GM-CSF) Pivotal Trial in Melanoma (OPTIM) trial are discussed in this article...
  2. pmc First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients
    Neil L Berinstein
    Sunnybrook Health Sciences Center, Toronto, ON, Canada
    J Transl Med 10:156. 2012
    ..Naturally processed HLA-A2 restricted peptides presented by breast, ovarian and prostate cancer cells were used as antigens to create a therapeutic cancer vaccine, DPX-0907...
  3. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  4. pmc Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression
    Xiulong Xu
    Department of General Surgery, Rush University Medical Center, Chicago, IL 60612, USA
    BMC Cancer 11:194. 2011
    ..In this study, we sought to study MICA/B expression in pancreatic cancer and to determine whether and how genotoxic drugs such as gemcitabine can affect MICA/B expression and natural killer cytotoxity...
  5. doi request reprint Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma
    Howard L Kaufman
    Department of Surgery, Medicine and Immunology, Rush University Medical Center, Chicago, IL, USA
    Ann Surg Oncol 17:718-30. 2010
    ..The work reported herein was performed to better characterize the effect of vaccination on local and distant antitumor immunity...

Research Grants8

  1. ALVAC-CEA-B7 VACCINE TREATMENT OF ADVANCED CEA EXPRESSING ADENOCARCINOMAS
    Howard Kaufman; Fiscal Year: 2001
    ..Patients without progression may be re-vaccinated. ..
  2. ENHANCING TUMOR VACCINES WITH CO-STIMULATORY MOLECULES
    Howard Kaufman; Fiscal Year: 2004
    ..This may have important implications for the future design of tumor vaccines in melanoma and other settings. ..